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ABSTRACT 
The present study aimed at defining biomarkers and functional pathways for the optimization of 
chondrogenic differentiation in stem cell-based, autologous chondrocyte transplantation (MACT). 
First, biomarkers and pathways of chondrogenic differentiation were defined in cartilage 
regenerates after MACT/cartilage repair procedures by generating an atlas of differential gene 
expression between second look biopsies (2nd LB) and normal cartilage, osteoarthritis (OA) 
cartilage, or 3D-cultured chondrocytes using Affymetrix microarrays and bioinformatics. Target 
molecules/pathways were then validated by PCR and gene ontology analysis. The functional 
importance of the periostin-Wnt-MMP13 pathway was then addressed by silencing of periostin in 
OA chondrocytes and the analysis of target and phenotype genes at the mRNA and protein level. 
There was only limited similarity between 2nd LB and normal cartilage, indicating incomplete 
repair after cartilage replacement. On the other hand, similarities between 2nd LB and OA cartilage 
concerning the expression of inflammatory response genes suggested a contribution of 
inflammatory processes to the incomplete defect healing. Also, the overexpression of matrix 
degradation and mis-differentiation markers (including the periostin-Wnt-MMP13 pathway), 
indicated molecular abnormalities during insufficient cartilage repair. As a proof of concept, 
successful silencing of periostin in OA chondrocytes resulted in transient downregulation of tissue-
degrading MMP13 (mRNA and protein) and in upregulation of cartilage-specific collagen 2, 
pointing to favorable effects of periostin silencing on the chondrogenic phenotype and the 
formation of mature cartilage. Transient upregulation of the wound healing markers ICAM 1 and 
collagen 3, however, indicated that periostin silencing may concurrently augment the formation of 
scar tissue, requiring further refinement of the therapeutic molecular targets. 
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ABSTRAKT 
Ziel der aktuellen Studie war die Definition von Biomarkern und funktionellen Signalwegen zur 
Optimierung der chondrogenen Differenzierung in der Stammzell-basierten autologen 
Chondrozyten Implantation (MACT). Zuerst wurden Biomarker und funktionelle Signalwege der 
chondrogenen Differenzierung in Knorpelregeneraten nach MACT/Knorpel-Reparatur durch die 
Etablierung eines differenziellen Genexpressions-Atlas zwischen „second look“ Biopsien (2nd LB) 
sowie normalem Knorpel, Osteoarthritis (OA) Knorpel und 3D-kultivierten Chondrozyten mittels 
„Affymetrix microarrays“ und Bioinformatik identifiziert. Zielmoleküle/Signalwege wurden 
mittels PCR und „gene ontology“ Analyse validiert. Dann wurde die funktionelle Bedeutung des 
Periostin-Wnt-MMP13 Weges durch das „silencing” von Periostin in OA Chondrozyten und die 
Analyse von Ziel- und Phänotyp-Genen adressiert. 
 
Es gab nur begrenzte Ähnlichkeiten zwischen 2nd LB und normalem Knorpel, ein Hinweis auf eine 
unvollständige Reparatur nach Knorpelersatz. Andererseits deuteten Ähnlichkeiten zwischen 2nd 
LB und OA Knorpel bei der Expression von Genen der Entzündungsreaktion auf einen Beitrag 
von Entzündungsprozessen zur unvollständigen Defektheilung hin. Außerdem wies die Über-
Expression von Markern des Matrix-Abbaus und der Fehl-Differenzierung (inkl. des Periostin-
Wnt-MMP13 Weges) auf molekulare Abnormalitäten während der insuffizienten 
Knorpelreparatur hin. Als „proof of concept” führte das erfolgreiche „silencing” von Periostin in 
OA Chondrozyten zur transienten Unterdrückung der Gewebs-abbauenden MMP13 (mRNA and 
protein) und Hochregulierung von Knorpel-spezifischem Kollagen 2 als Hinweis auf positive 
Effekte des Periostin „silencing” auf den chondrogenen Phänotyp und die Bildung von reifem 
Knorpel. Die transiente Hochregulierung der Wundheilungsmarker ICAM 1 und Kollagen 3 
deutete jedoch an, dass das Periostin „silencing” gleichzeitig zu einer Verstärkung der 
Narbenbildung führt, was die Notwendigkeit zur verfeinerten Auswahl der therapeutischen 
Zielmoleküle belegt. 
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1 INTRODUCTION 
1.1 Epidemiology of cartilage defects 
Cartilage defects are one of the top ten most disabling diseases in the industrialized countries. 
Traumatic and osteoarthritis defects possess a very limited spontaneous regeneration capacity and 
often result in dramatic loss of cartilage, which may lead to partial or complete loss of joint 
function. This represents a therapeutic challenge, particularly in young and active individuals [1]. 
Such defects result in considerable pain and reduction of the quality of life for the affected 
individual, but also cause an enormous socioeconomic impact due to work disability and 
ambulatory or stationary therapy. During the past 25 years, promising new strategies have emerged 
using assorted scaffolds and cell treatments with expanded chondrocytes [2-4]. Current techniques 
for the repair of joint cartilage defects (e.g., microfracturing of the subchondral bone plate or 
matrix-/scaffold-assisted, autologous chondrocyte transplantation [MACT]) have so far not 
resulted in complete healing of the defect with the formation of fully mature (hyaline-like) 
cartilage. This shows the prevailing need to understand cartilage biology and the mechanisms of 
cartilage damage and remodeling in cartilage pathology, for example during the development of 
OA or aging, with the aim to improve therapeutic strategies to prevent cartilage damage and 
promote repair [5]. The aim of the current study was to better understand the molecular processes 
underlying cartilage healing by high quality, comparative molecular network analysis and the 
identification of key biomarkers supporting or preventing complete regeneration of the injured 
cartilage. 
1.2 Cartilage 
Cartilage, one of the main types of connective tissue, is a tough, flexible tissue that covers and 
protects the ends of long bones in the joints and serves as a structural component of rib cage, ear, 
nose, bronchial tubes, intervertebral discs, and other body components. There are three different 
types of cartilage in the body. Elastic cartilage is found in the ear, part of the nose, and the trachea, 
fibrous cartilage occurs for example in specialized cartilage pads called menisci, and hyaline or 
articular cartilage is found in joints, the septum of the nose, and the trachea.  
1.2.1 Structure of articular cartilage 
Human articular cartilage is a highly specialized tissue with a thickness of 2 to 4 mm, which 
provides the low-friction gliding essential for physiological joint function [6]. It consists of a dense 
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extracellular matrix (EMC) with sparsely distributed, specialized chondrocytes (1-5% v/v). The 
articular cartilage is differentiated into a thin superficial (tangential) zone which protects the 
deeper layers from the compressive forces (Fig. 1). Immediately below the superficial zone is the 
middle (transitional) zone, which acts as an anatomic and functional bridge between the superficial 
and deep zones. The middle zone occupies approx. 40% to 60% of the total cartilage volume and 
shows an increasing relative concentration of proteoglycans and a decreasing concentration of 
collagen, which results in decreased tensile strength and increased pressure loading capacity. The 
deep zone takes up approx. 30% of the articular cartilage volume and provides the greatest 
resistance to compressive forces. The tide mark situated beneath separates the deep zone from the 
calcified cartilage, which shows a scarce cell population of hypertrophic chondrocytes and plays 
an integral role in connecting cartilage to bone by anchoring the collagen fibrils of the deep zone 
in the subchondral bone (Fig. 1). 
Figure 1: Principal structure of hyaline cartilage with its different layers [7]. 
1.2.2 Composition of articular cartilage 
The extracellular matrix (ECM) of the articular cartilage contains between 65 and 80 mass % of 
water. This high-water content allows load-dependent deformation of the cartilage and provides 
nutrition and medium for lubrication, creating a low-friction gliding surface. Collagen fibers, 
which represent 10–20% of the wet weight of articular cartilage, are the second major component. 
Cartilage-specific collagen II forms the principal component of the macrofibrillar framework, 
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which provides tensile strength to the articular cartilage. Table 1 shows the different types and 
functions of the collagens found in articular and calcified cartilage [8, 9]. 
 
Collagen type  Morphological location  Function  
I Healed cartilage Formation of calcified cartilage/scar 
II Major macrofibril component (≤ 95%) Provision of tensile strength  
III Matrix Matrix maturation, tissue healing 
VI  Pericellular matrix  Chondrocyte-matrix attachment  
V Matrix Component of bone matrix 
IX  Cross-linked to surface of 
macrofibrils  
Tensile strength; inter-fibrillar 
junctions 
Table 1: Types of collagens and their functions in articular cartilage, calcified cartilage, and bone. 
Proteoglycans are another major component of articular cartilage. These protein polysaccharides 
constitute 10–20% of its wet weight and provide compressive strength to the articular cartilage. 
There are two major classes of proteoglycans in articular cartilage, i.e., the large aggregating 
proteoglycan (aggrecan) and small proteoglycans, including decorin, biglycan, and fibromodulin. 
Proteoglycans are produced inside the chondrocytes and then secreted into the ECM [10]. Main 
functions of the chondrocytes are to synthesize various matrix components, also including 
dermatopontin  (DPT; [11]) and to regulate the matrix metabolism [2, 12]. 
1.3 Cartilage degradation 
Articular cartilage is devoid of blood vessels, lymphatics, and nerves and has a unique ability to 
withstand the high cyclic loads associated with the harsh biomechanical environment in the joint. 
Surprisingly, however, articular cartilage has a limited capacity for intrinsic healing and repair. 
Preservation and health of the articular cartilage are paramount for proper joint function. Due to 
its role as a cushion for bone articulation, articular cartilage is subject to many types of damaging 
insults, including decades of wear and tear, as well as acute joint injuries. Throughout life, the 
tissue undergoes continual internal remodeling as the cells replace matrix macromolecules lost 
through degradation [7]. When the catabolic activity is increased, lost cartilage is not completely 
replaced, neither quantitatively nor qualitatively. Consequently, articular cartilage progressively 
deteriorates and is eventually eroded, exposing the subchondral bone to the joint space, triggering 
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inflammation and osteophyte development, and generating severe pain and joint incapacitation [6]. 
This is the case in a major degenerative joint disease such as osteoarthritis (OA) [13]. There is a 
cascade of molecular phenomena occurring during the process of cartilage degradation. 
1.3.1 Molecular Pathology of Cartilage degradation 
OA strongly affects cartilage biology and leads to progressive cartilage degradation. During the 
development of OA, normal, quiescent chondrocytes become activated and undergo a phenotypic 
shift, resulting in fibrillation and degradation of cartilage matrix [14]. In healthy cartilage, 
chondrocytes respond to their microenvironment to maintain a delicate balance between synthesis 
and degradation of the ECM, the major components of which are type II collagen and aggrecan 
[15]. In OA, the water content in the EMC rises to more than 90% due to increased permeability 
and disruption of the matrix. This leads to a decreased modulus of elasticity and thus a reduction 
of the load bearing capability of the articular cartilage [12]. When the normal physiological 
mechanisms maintaining the matrix equilibrium fail, ECM components are lost, expanded 
chondrocytes cluster in the depleted regions, an oxidative state is induced in the stressed cellular 
environment, and, ultimately, chondrocyte apoptosis occurs [15-17]. Failure of the matrix 
equilibrium is due to increased expression of matrix-degrading enzymes [18], inhibition of matrix 
synthesis [19], and excessive production of pro-inflammatory mediators, such as cytokines, 
chemokines, and matrix degradation products [19, 20]. 
1.3.2 Pro-Inflammatory Cytokines 
The increased production of pro-inflammatory cytokines is a typical cartilage response and one of 
the key factors for cartilage degeneration in OA [21]. The cytokines IL-1β, IL-6, and TNF-α play 
a central role in the pathogenesis and disease severity of OA. During the development of OA, 
the IL-1β expression in the OA synovial fluid and membrane is elevated. IL-1β strongly induces 
the expression and release of proteolytic enzymes, such as matrix metalloproteinases (MMPs) 
and aggrecanases, and suppresses the expression of ECM components, including type II 
collagen and aggrecan. Other inflammatory cytokines such as TNF-α promote the production 
of nitric oxide (NO), a potent catabolic and pro-apoptotic mediator, in the synovial tissue. The 
cytokines thus directly and indirectly contribute to the destruction of the structural cartilage 
components. 
1.3.3 Proteases 
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Proteolytic cleavage of the major components of the cartilage extracellular matrix is executed by 
the ‘a disintegrin and metalloproteinase with thrombospondin motifs’ (ADAMTS) family 
members. These proteases are synthesized by chondrocytes and synovial cells in response to 
inflammatory stimuli. Metalloproteases are involved in the initial steps of matrix breakdown. 
Chondrocyte-derived matrix metalloproteinases (MMPs) and ADAMTSs family members [22] are 
the main enzymes involved in the breakdown of cartilage collagens and proteoglycans. 
1.3.4 The MMPs 
MMPs are a class of enzymes involved in the degradation of extracellular matrix molecules and in 
tissue remodeling. Under physiological conditions, MMP synthesis, activation, and activity are 
tightly regulated. For this reason, all MMPs are synthesized as inactive proenzymes. Critical 
pathways such as the Wnt pathway play an important role in the activation of the MMPs. For 
example, the Wnt-induced signalling protein 1 (WISP-1) increases the expression of MMPs. 
Among the MMPs, MMP1, 8, and 13 are highly specific, since they are the only ones capable of 
degrading native fibrillar collagen. MMP13 is by far the most studied MMP concerning its role in 
cartilage, as it is the major catabolic effector in osteoarthritis and other forms of cartilage 
degradation, owing to its robust ability to cleave the predominant collagen type II in articular 
cartilage. In addition to its main target type II collagen, the enzyme also cleaves other matrix 
molecules such as types IV and IX collagen. If the expression of MMP13 in the joint is elevated, 
there is significant cartilage damage and a rapid progression of joint destruction [23]. One of the 
up-stream regulators of MMP13 expression during cartilage degeneration is periostin [24].  
1.4 Functional roles of periostin in cartilage degradation 
Periostin, also termed osteoblast-specific factor 2, is a 93 kDa, secreted, vitamin K-dependent, 
glutamate-containing matricellular protein. Periostin is constitutively present at low levels in most 
adult tissues and contributes to repair processes after injury, epithelial mesenchymal transition, as 
well as extracellular matrix restructuring and remodeling. Indeed, periostin is highly expressed at 
sites of injury or inflammation and in tumors within the adult organism and actively contributes 
to tissue degeneration, inflammation, fibrosis, and tumor progression (Fig. 2; [25]). For this 
purpose, periostin can associate with other critical extracellular matrix (ECM) regulators such as 
TGF-β and induce the production of pro-inflammatory chemokines [26]. 
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Figure 2: Functional roles of periostin in various tissues. 
 
Periostin contributes to cartilage degeneration in OA through induction of MMP13 expression via 
Wnt signaling (Fig. 3A; [24, 27]). However, the molecular mechanisms underlying this process 
are still poorly understood. Periostin is expressed in eight isoforms, which are differentially 
expressed in various organs, and some of which appear to have tissue-specific functions [28-31]. 
This on one hand renders therapeutic targeting of periostin a complex molecular biological task, 
but on the other hand creates the theoretical possibility of selectively targeting cartilage-specific 
isoforms to prevent or reduce cartilage degeneration in OA [32]. Direct and indirect down-stream 
targets of periostin include MMP3 and MMP13  [24, 33], the TGF-β-interacting ECM molecule 
dermatopontin (DPT; [34]), the opoid polypetide hormone proenkephalin (PENK; also increased 
in psoriasis [35] and hypermethylated in prostate and colorectal cancer [36, 37]), and the 
intercellular adhesion molecule 1 (ICAM 1; Fig. 3)[38]. 
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Figure 3: Periostin actions on MMP13 (via Wnt signaling) and ICAM1. 
1.5 Cartilage regeneration 
Unfortunately, cartilage damage in humans is not readily repaired, in part because cartilage 
doesn’t have its own blood supply to readily provide regeneration-promoting factors. There are 
many novel therapeutic approaches aimed at restoring the composition, structure, and 
functional properties of normal human adult articular cartilage, e.g., engineering of tissue 
implants, use of tissue scaffolds, and application of growth and differentiation factors [4, 6, 39-
43]. However, such therapies often fail to promote the formation of fully mature cartilage [6]. 
1.5.1 Treatment strategies 
Recently, several repair techniques have been established for the treatment of cartilage lesions, 
e.g., cell-free (bio-engineered scaffolds, cell-free OCT from commercial banks; [1, 3, 40]), cell-
based ((M)ACT, OAT), and stem cell-directed procedures (micro-abrasion, Pridie-drilling). 
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1.5.2 Debridement and Lavage 
Debridement includes the removal of loose joint bodies and the smoothening of the cartilage 
surface, whereas mostly arthroscopic joint lavage eliminates up to 14 digestive, oxidative 
enzymes derived from chondronecrosis. However, these cleaning and rinsing techniques only 
ablate pain and reduce inflammation, but do not repair damaged articular cartilage [44].  
1.5.3 Cartilage abrasion 
This technique removes worn-out layers of the cartilage and “refreshes” the surface. It is very 
simple and fast, but often does not yield a sufficient long-term outcome [44]. 
1.5.4 Microfracturing (MF) 
MF (previously Pridie-Drilling) enables mesenchymal stem cells to migrate into damaged 
cartilage, differentiate at this site, and build new cartilaginous tissue. However, the regenerate 
often does not match the properties of the original cartilage, but represents fibrocartilaginous 
scar tissue, questioning the ability of MF to improve cartilage regeneration [44]. 
1.5.5 Osteochondral autologous transplant (OAT) 
An osteochondral autologous graft of the size of the defect is harvested from a region of the joint 
that is less exposed to mechanical strains than the original defect site. Then the graft is inserted 
into the defect by the press-fit technique. One advantage of this method is a very good healing 
rate at the insertion site. However, the damage at the harvest site and an often imperfect 
alignment of the tidemarks of graft and defect limit the use of this technique [45]. 
1.5.6 Cell-free, tissue-engineered scaffolds 
Tissue-engineered scaffolds, sometimes combined with microfracturing, e.g., stem cell-based, 
autologous matrix-induced chondrogenesis (AMIC), are designed to imitate cartilage structure 
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and to support cell immigration and the formation of high-quality hyaline cartilage. Advantages 
of these cell-free approaches are rapid commercial availability, convenient handling, one-time 
operation procedures, and no need for autologous donor sites or tissue donors [46]. 
1.5.7 (Matrix-associated) autologous chondrocyte transplantation (M) ACT 
During a first intervention, cartilage is arthroscopically harvested from the joint in an area less 
exposed to mechanical strain. Chondrocytes are then enzymatically liberated from the ECM and 
expanded in culture. Then the chondrocytes are implanted into the defect site, either by injection 
into a chamber below a fixed periostal flap or by seeding the cells onto a scaffold and subsequent 
insertion into the defect. Depending on the defect location, this can lead to very good clinical 
results, especially when treating defects with diameters  4 cm². However, one pitfall of this cost-
intensive procedure is that it requires two interventions [39, 41, 47, 48].
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2 OBJECTIVES OF THE STUDY 
The aim of this project was to define biomarkers and functional pathways for the optimization of 
chondrogenic differentiation in stem cell-based, matrix-assisted, autologous chondrocyte 
transplantation (MACT). This was pursued by comparing 2nd look biopsies (2nd LB) from patients 
with MACT/cartilage repair procedures to normal cartilage on one hand and to bone marrow-
derived, human MSC differentiating into chondrocytes on the other hand. The focus of our studies 
were potential deficits (e.g., de- or mis-differentiation) of successful and functional cartilage repair 
following MACT. For this purpose, the following steps were pursued: 
• Definition of biomarkers and pathways of chondrogenic differentiation in cartilage 
regenerates after MACT by generating an atlas of differential gene expression between 
2nd LB and normal cartilage, OA cartilage, or 3D-cultured chondrocytes using 
Affymetrix microarrays and self-organizing maps (SOM) 
• Validation of molecules/pathways underlying impaired cartilage repair by PCR and 
gene ontology analysis 
• Selection of the periostin-Wnt-MMP13 pathway for further functional analysis   
• Assessment of the functional importance of this pathway for the de- or mis-
differentiation of chondrocytes by silencing of periostin in OA chondrocytes and 
analysis of target and phenotype genes on the RNA and protein level  
• Discussion of the potential value of this pathway for the improvement of cartilage 
repair and the development of novel treatments for articular cartilage defects 
MATERIALS AND METHODS 
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3 MATERIALS AND METHODS 
3.1 Materials 
Chemical Substance Supplier 
-Mercaptoethanol Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Acetone  Carl Roth GmbH + Co. KG, Karlsruhe, Germany  
Agarose-Gel  Invitrogen™, Carlsbad,CA, USA  
Aquatex™  Merck KGaA, Darmstadt, Germany  
CaCl2 Roche Diagnostics GmbH, Mannheim, Germany 
Eosin  Roche Diagnostics GmbH, Mannheim, Germany 
Ethanol > 99.5%  Roche Diagnostics GmbH, Mannheim, Germany 
Glycine Roche Diagnostics GmbH, Mannheim, Germany 
Hematoxyline  Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany  
HCl Roche Diagnostics GmbH, Mannheim, Germany 
KCl Roche Diagnostics GmbH, Mannheim, Germany 
KH2PO4 Merck KGaA, Darmstadt, Germany  
Methanol Roche Diagnostics GmbH, Mannheim, Germany 
NaCl Roche Diagnostics GmbH, Mannheim, Germany 
Na2HPO4. 2H2O Roche Diagnostics GmbH, Mannheim, Germany 
Safranin- O solution  Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany  
SDS pellets Roche Diagnostics GmbH, Mannheim, Germany 
TRIS Roche Diagnostics GmbH, Mannheim, Germany 
Tween 20 Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Table 2: List of chemicals. 
Reagent/Medium Supplier 
Ampicillin Gibco™, Thermo Scientific, Waltham, MA, USA. 
Collagenase P Roche Diagnostics GmbH, Mannheim, Germany. 
EcoRI New England Biolabs®,Hitchin, UK. 
FBS- Fetal Bovine Serum  Gibco® by life technologies™, Darmstadt, Germany  
Gentamicin (50 mg/mL) Gibco™, Thermo Scientific, Waltham, MA, USA. 
Lipfectimine Roche Diagnostics GmbH, Mannheim, Germany 
LightCycler® 480 SYBR Green I Master Roche Diagnostics GmbH, Mannheim, Germany  
MMP13 ELISA kit R&D Systems; Minneapolis, MN, USA 
One Shot ™ TOP10 Competent cells Invitrogen™, Carlsbad,CA, USA. 
Periostin ELISA kit Adipogen International, Liestal, Switzerland 
PerfeCTa SYBR Green SuperMix Quanta bio, Beverly, MA , USA 
PenStrep Gibco™, Thermo Scientific, Waltham, MA, USA. 
Pierce™ BCA Protein Assay Kit Thermo Scientific, Waltham, MA, USA 
Pronase E Sigma-Aldrich, Taufkirchen, Germany. 
RNeasy kit Qiagen, Hilden, Germany. 
Stealth™ RNAi ActinPosControl Invitrogen™, Carlsbad,CA, USA. 
Stealth™ RNAiNegContol Kit Invitrogen™, Carlsbad,CA, USA. 
SuperScript Invitrogen, Karlsruhe, Germany 
TOPO™ TA Cloning™ Kit Invitrogen™, Carlsbad,CA, USA. 
Trypsin-EDTA (0.05%) Gibco™, Thermo Scientific, Waltham, MA, USA 
West Femto Chemiluminescence HRP Substrate SuperSignal™, Thermo Scientific™, Invitrogen 
Table 3: List of reagents and media. 
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Dye/Antibody Supplier Cat. No. 
Beta actin R&D Systems Inc, Minneapolis, MN 937215 
MPP13 R&D Systems Inc, Minneapolis, MN 87512 
Periostin Abcam, Cambridge, UK ab152099 
Secondary anti body   
anti- Rabbit IgG-HRP Abcam, Cambridge, UK ab6721 
anti- mouse IgG-HRP Abcam, Cambridge, UK ab97046 
Table 4: List of antibodies. 
 
Consumable Supplier 
96 Well Microplate Essen Bioscience Inc., Pittsfield Charter Township, MI, USA 
Cap Strips, flat, PCR clean Eppendorf AG, Hamburg, Germany 
CELLSTAR® Cell culture flask Greiner Bio-One GmbH, Frickenhausen, Germany 
CELLSTAR® Multiwell plate (12 wells) Greiner Bio-One GmbH, Frickenhausen, Germany 
Cell scraper, 24 cm TPP Techno Plastic Products AG, Trasadingen, Switzerland 
Filter, 70 µm Corning® cell strainer, Sigma-Aldrich, Taufkirchen, Germany 
GeneChipR Hybridisation Oven 645 Affymetrix, Santa Clara, CA, USA 
Microscope slides Thermo Scientific, Waltham, MA, USA 
Table 5: List of consumables. 
 
Technical device/Instrument Supplier 
Affymetrix U133 Plus 2.0, GeneChip Affymetrix, Santa Clara, CA, USA 
Affymetrix Fluidics Station 450 Affymetrix, Santa Clara, CA, USA 
Axiovert 25 inverse microscope Carl Zeiss Microscopy GmbH, Jena, Germany 
Cell Coulter Beckman Coulter GmbH, Krefeld, Germany 
Centrifuge 5417C Eppendorf AG, Hamburg, Germany 
Centrifuge 5415R Eppendorf AG, Hamburg, Germany 
Centrifuge 5810R Eppendorf AG, Hamburg, Germany 
CLARIOstar® microplate reader BMG LABTECH, Orthenberg, Germany 
Cell Counter Cellometer Auto T4, Nexcelom, Massachusetts, USA 
Eppendorf Mastercycler Eppendorf, Hamburg, German 
GeneChip Scanner 3000 Affymetrix, Santa Clara, CA, USA 
Incubator HERAcell 240i CO2 Thermo Scientific, Waltham, MA, USA 
Mastercycler® ep realplex4 Eppendorf AG, Hamburg, Germany 
Multichannel pipette Eppendorf AG, Hamburg, Germany 
NanoDropTM 2000 Spectrophotometer PEQLAB Biotechnology GmbH, Erlangen, Germany 
PowerPac 200 power supply Bio-Rad Laboratories, Inc., Hercules, CA, USA 
Thermomixer comfort Eppendorf AG, Hamburg, Germany 
Titramax 1000 shaker Heidolph Instruments GmbH, Schwabach, Germany 
Trans-Blot Turbo Transfer System Bio-Rad Laboratories, Inc., Hercules, CA, USA 
Table 6: List of technical devices and instruments. 
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3.2 Patient material 
3.2.1 Patient material for Affymetrix analyses 
Cartilage was obtained from the knee joints of 5 OA patients who underwent joint replacement 
surgery (samples V4-V8; OA grade 2-3 according to Ahlbäck; Mankin score  4; [49]); normal 
cartilage (V1-V3 and V13-V16) was harvested from the medial and lateral femoral condyle of 7 
adult multi-organ donors within 12-14 h post mortem ([49]; approved by the ethics committees of 
the Medical Faculties at Gothenburg University and Charité-Universitätsmedizin Berlin). 
Samples V9-V12 contained 2nd LB (weight 10 to 50 mg) of patients with traumatic/degenerative 
cartilage defects previously treated with MACT with persistent joint swelling and/or pain (n = 4; 
mean follow-up approx. 3 years, median 1.6 years; see Table 19 on page 45; approved by the ethics 
committee of the Medical Faculty, Friedrich Schiller University Jena). Samples V17-V27 were 
isolated from normal cartilage [50], expanded in monolayer until the end of passage 0 (V26, V27), 
and then re-differentiated in 3D culture in fibrinogen for 7 days (V17, 20, 23), 14 days (V18, 21, 
24) or 21 days (V19, 22, 25). 
3.2.2 Patient material for silencing experiments 
Tibia plateaus or femoral heads cylinders were collected under sterile conditions in phosphate-
buffered saline (PBS) from six OA patients (age range 55-76 years), who underwent total knee or 
hip replacement surgery at the Department of Orthopedics, Jena University Hospital, 
Waldkrankenhaus “Rudolf Elle”, Eisenberg, Germany. Informed patient consent was obtained and 
the study was approved by the Ethics Committee of the Medical Faculty, Friedrich Schiller 
University Jena. In the cell culture laboratory, cartilage slices of approximately 4 mm2 were 
carefully removed from the underlying bone, washed twice in PBS, and then digested for 1 hour 
at 37°C and 5% CO2 (HERAcell 240i CO2, Thermo scientific, Waltham, MA, USA) in a spinner 
flask in serum-free DMEM/F12 (DMEM/F12; Invitrogen, Karlsruhe, Germany) containing 0.1% 
pronase E (Sigma-Aldrich, Taufkirchen, Germany). After two further washes with pre-warmed 
PBS at 37°C, overnight enzymatic digestion was performed at 37°C in 0.05% collagenase P 
(Roche Diagnostics, Mannheim, Germany) in DMEM/F12 media supplemented with 10% fetal 
calf serum (FCS). Cells were separated by filtration through a 70 μm mesh sieve (Corning® cell 
strainer, Sigma-Aldrich, Taufkirchen, Germany) and centrifuged for 15 min at 1,500 rpm 
(Centrifuge 5417C).  The pellet was washed in PBS containing 10% FCS and centrifuged again 
for 5 min at 1,500 rpm for a total of three times. Subsequently, the cells were resuspended in 1 ml 
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culture medium (DMEM/F12; 5% FCS; 1% Gentamicin; 5% pen/strep), counted in a Cellometer 
Auto T4 Bright Field Cell Counter, and then seeded into a 225 ml cell culture flask (1 x 107 
cells/flask), with medium changes every second day. Chondrocytes were subcultured after 
reaching 90% confluence by incubation for 5 min at 37°C in 0.05% trypsin-EDTA (Versene, 
Gibco), centrifugation, and washing in PBS and used for experiments at passage 1.  
3.3 Histological evaluation 
3.3.1 Hematoxylin and eosin staining 
Paraffin sections of the 2nd LB were cut into 6-µm sections and stained with hematoxylin (nuclei) 
and eosin (cytoplasm; H&E) for histolopathological evaluation [51]. The sections were 
deparaffinized with xylene, hydrated by passage through decreasing concentrations of alcohol 
(100%, 90%, 80%, 70%), dipped for 10 min in hematoxylin, blued under running tap water, stained 
for 10 min in eosin, and finally washed again in distilled water. 
3.3.2 Safranin-O Staining  
Safranin O staining was used to assess the proteoglycan content [52]. After deparaffinization and 
hydration, the sections were stained for 10 min with Safranin O, washed with distilled water, 
exposed for 10 min to Fast Green stain, and again washed with distilled water. 
3.4 Labelling and microarray hybridization 
Total RNA samples were hybridized to Human Genome U133 Plus 2.0 arrays using the GeneChipR 
Expression 3`IVT Express Kit, GeneChipR Hybridisation Oven 645, Affymetrix Fluidics Station 
450, and GeneChip Scanner 3000 (all Affymetrix, Santa Clara, CA, USA). Data analysis was 
performed using MAS 5.0 (Microarray Suite statistical algorithm; Affymetrix) and observing 
MIAME criteria (http://www.mged.org/Workgroups/MIAME/miame.html). 
3.5 Bioinformatic data analysis 
Affymetrix data were pre-processed and normalized using the Bioconductor package affy [53]. 
Normalized expression data were analyzed by self-organizing maps (SOM) methods using the 
Bioconductor package oposSOM [54]. This analysis included all samples and was performed on 
20 x 20 metagenes.  D-cluster analysis was used to identify subsets of differentially expressed 
genes. Expression of these subsets in the individual samples was characterized using Gene Set Z-
score (GSZ-score; ekhidna.biocenter.helsinki.fi/users/petri/public/GSZ/GSZscore.html). 
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3.6 Silencing of Human Periostin 
Silencing of Periostin (POSTN) in human OA chondrocytes was performed using the siRNA 
technique and the Stealth™ RNAi ActinPosControl (12953-141; Invitrogen), with the 2 silencing 
constructs G05, and A02 (Table 7; Fig. 4). The Stealth™ RNAiNegContol Kit (12935-100) was 
used as a silencing control, an untouched water control was also maintained. 
 
Stealth™ RNAi 
Actin Pos 
Sequence Targeted Periostin 
isoforms 
Post siRNA G05 GAGACACGAGAAGAACGAACATTA 1, 2, 3, 4, 5, 8 
Post siRNA A02 CCATGGGAACCAGATTGCAACAAAT 1, 2, 3, 4, 5, 6, 7, 8 
 
Table 7: siRNA constructs (sequence and targeted periostin isoforms). 
Figure 4: Position of siRNA constructs and PCR primers for periostin (total and isoforms); E = 
exon; bp = base pairs; IF= isoform. 
For the analysis of mRNA Expression by PCR, the reagents (Table 8) were mixed and incubated 
for 20 min at room temperature to allow complex formation. Then 202.6 µl of the mixture were 
aliquoted into each well of a 12-well plate for the 2 time points (2 and 4 days), followed by addition 
of 1 ml each of culture medium (DMEM/F12; 10% FCS) with pre-diluted cells (2.5 x 105), 
incubation of the plates for 24 h, careful draining of the culture medium, and addition of 1 ml of 
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fresh culture medium (DMEM/F12; 5% FCS; 1% Gentamicin; 5% pen/strep) for 2 and 4 days. 
RNA was extracted and used to analyze the expression of different target and marker genes 
expression by PCR (see 3.6.2 below). The supernatant was stored at -80°C and later used for 
enzyme-linked immunosorbent assays (ELISA; see 3.8.2 below). 
 
RNA expression silencing (two time points: 2 and 4 days) 
Reagents 
Untouched 
Control 
Silencing  
Control 
G06 G05 A02 
Opti-MEM®  400 µl 400 µl 400 µl 400 µl 400 µl 
siRNA 
1.2 µl 
(water) 
 1.2 µl 1.2 µl 1.2 µl 1.2 µl 
Lipofectamine™ 4 µl 4 µl 4 µl 4 µl 4 µl 
  
Table 8: Volume of reagents required for the silencing of the RNA expression. 
 
For the analysis of cellular protein, a five-fold volume of the reagents in Table 8 was used for the 
transfection of 5 x 105 cells for 24 h in six-centimeter petri plates with 5 ml of culture medium 
(DMEM/F12; 10% FCS), followed by replacement with 5 ml of fresh culture medium 
(DMEM/F12; 5% FCS; 1% Gentamicin; 5% pen/strep) for 2 and 4 days. Subsequently, the protein 
was extracted and the concentrations of MMP13 and periostin were analyzed. 
3.7 RNA isolation, cDNA preparation, and real-time RT-PCR analysis 
3.7.1 RNA isolation 
The RNeasy kit (QIAGEN) was used to isolate the RNA. Briefly, 2.5 x 105 cells were lysed on ice 
in 350 µl lysis buffer containing 0.1% (v/v) mercaptoethanol. After centrifugation for 3 min at 
10,000 rpm, the supernatant was removed carefully, 1 volume of 70% ethanol was added to the 
pellet, and the mixture was homogenized using a pipette.  The mix was transferred to a RNeasy 
mini spin column, placed on a 2 ml collecting tube, and centrifuged at 8,000 rpm for 15 sec. The 
flow through was discarded, 700 µl RW1 buffer were added to the spin column, and the column 
centrifuged for 15 sec at 8,000 rpm. Then 500 µl RPE buffer were added to the spin column and 
centrifuged at 10,000 RPM for 1 min, followed by addition of 500 µl RPE buffer and centrifugation 
at 8,000 RPM for 2 min. The spin column was placed on a new 1.5 ml collecting tube and the RNA 
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eluted by adding 30-50 µl of RNase-free water and centrifugation at 8,000 rpm for 1 minute. The 
RNA concentration was measured using a nano drop spectrophotometer (NanoDropTM 2000; 
Thermo Fisher Scientific, Waltham, MA, USA) and stored at -80°C. 
3.7.2 cDNA preparation 
cDNA (20 µl) was prepared from total RNA using oligo-dT primers and SuperScript reverse 
transcriptase (Invitrogen, Karlsruhe, Germany). The RNA concentration was measured in a nano 
drop and the required RNA volume calculated by dividing 360 by the RNA concentration (X ng/µl).  
Using a nuclease-free microcentrifuge tube, 1 µl of Oligo dt, 1 µl of dNTP MIX (10 mM each), x 
µl of RNA and y µl of sterile distilled water were added to result in a total volume of 12 µl.  The 
mixture was heated to 60oC for 5 min, quickly chilled on ice, and centrifuged for 10 sec to collect 
the condensate on the bottom of the tube. Then 4 µl of 5 X first strand buffer, 2 µl of 0.1 M DDT, 
and 1 µl of water were added, gently mixed, and incubated at 42oC for 2 min, followed by addition 
of 1 µl of superscript II RT, incubation at 42oC for 50 min, and inactivation of the enzyme by 
heating to 70oC for 15 min. The cDNA was stored at -20oC and used for RT-PCR. 
3.7.3 Quantitative real-time RT-PCR analysis 
In addition to cartilage and bone markers, the expression of differentially expressed genes was 
validated by quantitative real-time PCR in an Eppendorf Mastercycler (Eppendorf, Hamburg, 
Germany). The expression levels of mRNA were normalized to the expression of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). PCR reaction was performed in a total volume of 20 µl. 
The mix was prepared (Table 9) and the mRNA expression was analyzed using a PCR machine 
(Eppendorf, Hamburg, Germany). 
RT PCR  Master Mix 
Reagent Amount 
PerfeCTa SYBR® Green FastMix 10 µl 
RNase-Free Water 8.2 µl 
Forward primer 0.4 µl 
Reverse primer 0.4 µl 
cDNA 1 µl 
 
Table 9: Master mix preparation for 20 µl reaction. 
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Forward and reverse primers (Jena Bioscience GmbH), product size, annealing and melting 
temperatures for all genes are shown in Table 10. The CT values of the genes were analyzed using 
2-∆∆CT method [55]. 
 
Gene symbol 
 
Sequence 
 
 
Primers (5′–3′) 
 
Product size 
(bp) 
 
Annealing 
temperature, 
˚C 
 
Melting 
temperature, 
˚C 
GAPDH NM_001289746.
1 
Forward CGGAGTCAACGGATTTGG 307 60 80 
Reverse AGCCTTCTCCATGGTGGTG 
MMP13 NM_002427.3 Forward CACCGGCAAAAGCCACTTT
A 
119 60 80 
Reverse GGTCACATTTGTCTGGCGTT 
Total 
Periostin 
(POSTN) 
Isoforms (IF) 
1-8 
NM_006475.2 Forward CAGCAGACACACCTGTTGG
A 
622 (IF 1) 
451 (IF 2) 
457 (IF 3) 
367 (IF 4) 
541 (IF 5) 
361 (IF 6) 
277 (IF 7) 
538 (IF 8) 
60 68 
Reverse CACTGAGAACGACCTTCCC
T 
Periostin 
Isoform 1 
NM_006475.2 Forward AGGCAGTCTTCAGCCTATTA
TCA 
333 
 
60 68 
Reverse TGACCATCACCACCTTCAAT
G 
Periostin 
Isoform 2 
NM_001135934.
1 
Forward CCCCGTGACTGTCTATAAGC
C 
228 
 
62 68 
Reverse TGACCATCACCACCTTCAAT
G 
Periostin 
Isoform 3 
NM_001135935.
1 
Forward ACTGTCTATAGACCCACAC 282 
 
62 68 
Reverse CCTCACGGGTGTGTCTTCTT
G 
Periostin 
Isoform 4 
NM_001135936.
1 
Forward CCCCGTGACTGTCTATAAGC
C 
199 
 
62 68 
Reverse CCTCACGGGTGTGTCTTCTT
G 
Periostin 
Isoform 5 
NM_001286665.
1 
Forward ACTGTCTATAGACCCACAC 311 
 
62 68 
Reverse TGACCATCACCACCTTCAAT
G 
Periostin 
Isoform 6 
NM_001286666.
1 
Forward CCGTAGCTGTCTATAGTCCT
CA 
136 
 
62 68 
Reverse TGACCATCACCACCTTCAAT
G 
Periostin 
Isoform 7 
NM_001286667.
1 
Forward CCGTAGCTGTCTATAGTCCT
CA 
107 
 
62 68 
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Reverse CCTCACGGGTGTGTCTTCTT
G 
Periostin 
Isoform 8 
NM_001330517.
1 
Forward AGGCAGTCTTCAGCCTATTA
TCA 
301 
 
62 68 
Reverse CACGGGTGTGTCTTCTTGTA
AC 
MMP3 NM_002422.4 Forward TGAGGACACCAGCATGAAC
C 
248 
 
60 81 
Reverse ACTTCGGGATGCCAGGAAA 
DPT NM_001937.4 Forward CAGGATTCCAGAGCCGCTA
C 
  92 
  
60 80 
Reverse GCAGGAATATGGGCACCTC
T 
PENK  
 
NM_001135690.
2 
Forward TCCTGGCTTGCGTAATGGA
A 
148 60 80 
Reverse TGGCTTTCTTCCGGTTTGCT 
ICAM1 NM_000201.2 Forward CCTTCCTCACCGTGTACTGG   92 
 
60 80 
Reverse GCAGCGTAGGGTAAGGTTC
T 
COL1A1 XM_005257059.
4 
Forward TGGAGCAAGAGGCGAGAG 122 60 80 
Reverse CACCAGCATCACCCTTAGC 
COL2A1 XM_017018831.
1 
Forward CAACCAGGACCAAAGGGAC
A 
252 60 80 
Reverse CTGGGCAGCAAAGTTTCCA
C 
COL3A1 NM_000090.3 Forward CGCCCTCCTAATGGTCAAG
G 
161 60 80 
Reverse TTCTGAGGACCAGTAGGGC
A 
COL5A1 NM_000093.4 Forward CTACGTGGACTACGCGGAC 286 60 80 
Reverse CCAAGAAGTGATTCTGGCC
CC 
COL9A2 XM_011540717.
2 
Forward AGGGCCTTCCTGGATTCTCT 219 60 80 
Reverse CCTTGTCTCCTTTGACGCCT 
ACAN XM_017021987.
1 
Forward TGCATTCCACGAAGCTAAC
CT 
82 60 80 
Reverse CGCCTCGCCTTCTTGAAAT 
 
Table 10: Primer pairs for target and marker genes and PCR conditions (product size, annealing 
temperature, melting temperature). 
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3.8 Clonal analysis of the periostin isoform frequency in OA chondrocytes 
3.8.1 Ligation 
Ligation is the joining of two nucleic acid fragments by an enzyme. A sticky end ligation of the 
total periostin PCR product was performed using the TOPO™ TA Cloning™ Kit (Invitrogen). The 
amount of PCR product required for ligation depends on its DNA concentration. The reagents 
(Table 11) were mixed and the ligation mixture was incubated at 11oC overnight. 
Reagent Amount 
Total Periostin PCR Product 0.5–4 µL 
Sterile Water add to a total volume of 4 µL 
Salt Solution 1 µL 
TOPO® Vector 1 µL 
Final Volume  6 µL 
 
Table 11: Volume of reagents required for ligation of PCR product. 
3.8.2 Transformation 
Competent cells (One Shot ™ TOP10 Chemically Competent E. coli, Invitrogen) were thawed on 
ice for 10 min, mixed with the ligation product, and again incubated on ice for 1 h. The cells were 
then subjected to a heat shock at 42oC for 20 sec and quickly returned to ice. Preheated SOC 
medium (250 µl; Invitrogen) was added and incubated on a heating block at 37oC for 1 h. 
Subsequently, the cells were centrifuged at 10,000 RPM for 10 sec, the medium exceeding 70 µl 
was tipped off from the tube, the pellet was mixed with SOC medium and plated on an LB 
agar+ampicillin (10000:1; v/v) petri plate (Table 12). 
LB agar medium - Mix at (60oC) 
Reagent Amount 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
Agar 15 g 
H2O 1 Liter 
Table 12: Reagents required for the preparation of Lysogeny broth (LB) agar medium. 
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3.8.3 Liquid bacterial culture for Mini Prep 
The colonies were picked using a sterile pipette tip and swabbed on to a new LB agar+amp 
(10000:1) plate. The pipette tip was then dropped into a glass test tube with 2 ml liquid broth+amp 
(Table 13) and incubated in a shaker incubator (Incubator 1000 © Heidolph Instruments GmbH) 
at 37oC for 16 h. 
LB medium – Mix at (45oC) 
Reagent Amount 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
H2O 1 Liter 
 
Table 13: Reagents required for the preparation of Lysogeny broth (LB) medium. 
3.8.4 Purification of Plasmid DNA 
The liquid miniprep culture was centrifuged at 13,000 rpm for 1 min and the pellet resuspended in 
100 µl of 50 mm TRIS/10 mm EDTA + rnase (4oC). Then 200 µl of 0.2 M NAOH/1% SDS was 
added, followed by 150 µl potassium acetate (1 M) and the mixture was shaken vigorously and 
then centrifuged at 13,000 rpm for 5 min. The supernatant was transferred into a tube with 700 µl 
of isopropanol (4oC) and centrifuged at 13,000 RPM for 10 min. The pellet was resuspended in 
300 µl of 70% ethanol and centrifuged at 13,000 RPM for 2 min, followed by drying for 5 min. 
The pellet was resuspended in 50 µl of water and the DNA concentration was measured.  
3.8.5 Restriction digestion 
Restriction digestion is an enzymatic technique to cleave DNA molecules at specific sequences. 
The purified plasmid DNA was tested for the frequency of periostin isoforms. The enzyme EcoRI 
(New England Biolabs®) was used to cleave the plasmid DNA. The nucleic acid recognition 
sequence of the enzyme is G/AATTC, which has a palindromic, complementary sequence of 
CTTAA/G. The reagents were mixed with the plasmid sample (Table 14) and incubated at 37oC. 
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EcoR1 Restriction digestion at (37oC) 
Reagent Amount 
Restriction enzyme 1 µl 
DNA 7 µl 
10 X NE buffer 2 µl 
Incubation time 1 h 
 
Table 14: Volume of reagents required for restriction digestion. 
After restriction digestion, 2 µl of gel loading dye were added and the sample was run on a 2% 
agarose gel at 100 volts for 30 min. Product sizes were determined using a 1 kD DNA ladder. 
Some of the periostin isoforms have EcoR1 sites in the center of the PCR product (Table 15). 
  
Periostin ISOFORMS 
Isoform EcoR1 Site 
Base Pairs (bp) 
before EcoR1 site  
Base Pairs 
after EcoR1 
site 
Product length (bp) 
Isoform 1 Present 240 382 622 
Isoform 2 Absent - - 451 
Isoform 3 Present 159 293 457 
Isoform 4 Absent - - 367 
Isoform 5 Present 159 382 541 
Isoform 6 Absent - - 361 
Isoform 7 Absent - - 277 
Isoform 8 Present 240 298 538 
 
Table 15: Properties of all isoforms present in the total periostin PCR product. 
3.9 Protein isolation and quantification  
After cultivation for 2 and 4 days, the cell plates were put on ice, washed thrice with ice-cold PBS, 
and incubated for 10 min with 350 µl of lysis buffer (50 mM Tris-Ci, pH 8.0, 150 mM NaCl, 1% 
Nonidet P40). The sample was scraped, collected into a 1.5 ml tube, and stored at -20oC. 
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3.9.1 BCA Protein Assay 
Protein content was determined using the bicinchoninic acid assay (BCA; Pierce, Thermo 
Scientific, Waltham, MA, USA ) following acetone precipitation of a 25 μl sample aliquot on ice 
for 30 min. Samples were centrifuged for 10 min at 13,000, the pellet resuspended in 50 μl of 0.1 
N NaOH, and then incubated on a hot plate at 60oC for 20 min under shaking (350 rpm). Tubes 
were spun briefly and loaded in 96-well plates. After addition of 200 μl color agent to samples and 
standard, the plate was incubated for 30 min at 37°C, cooled to room temperature, and measured 
at 562 nm.  
3.9.2 Enzyme-linked immunosorbent assay (ELISA) 
ELISAs are plate-based assays for detecting and quantifying peptides and proteins. 
3.9.3 Detection of Periostin 
Periostin concentrations in culture supernatants were measured using a competitive periostin 
ELISA kit (Cat. No. AG-45B-0004-KI01; Adipogen International, Liestal, Switzerland). Different 
dilutions of standard and diluted samples (100 µl each) were added in duplicate into 16-well strips, 
the plate was covered with adhesive strips and incubated for 2 hours at 37oC. Following aspiration 
of the liquid, 300 µl of 1 X wash buffer were added for 5 consecutive times. Then 100 µl of diluted 
detection antibody were added to each well, the plate was covered with adhesive strips and again 
incubated for 1 hour at 37oC, followed by 5 times washing in 300 µl of 1 X wash buffer. 
Subsequently, 100 µl of TMB substrate solution were added, and the color reaction was developed 
by incubation at RT in the dark for 10-20 minutes without covering the plate. After addition of 50 
µl stop solution, the optical density was determined at an OD of 450 nm using a microplate reader.   
3.9.4 Detection of MMP13 
MMP13 levels were measured by ELISA (Cat. No DY511; R&D Systems; Minneapolis, MN, 
USA). A 96-well plate was coated with diluted capture antibody overnight at room temperature 
(100 µl per well). After washing thrice with 400 µl wash buffer, the plate was blocked by adding 
300 µl of reagent dilution to each well, covered with an adhesive strip, and incubated for 1 hour at 
room temperature. After washing, each well was incubated for 2 hours at room temperature with 
100 µl of sample or serially diluted standard. After washing, 100 µl of detection antibody were 
added and the plate incubated for 2 hours at room temperature. Finally, 100 µl of Streptavidin-
HRP/well were added and the plate incubated for 20 min at room temperature in the dark. After 
adding 50 µl stop solution, the optical density at 450 nm was determined.   
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3.9.5 Western blot 
Western blotting, a technique to identify specific proteins in a mixture of cellular proteins, consists 
of: 1) size separation by denaturing SDS-PAGE (7%), 2) transfer to a solid support by 
electrotransfer, 3) detection of proteins with specific primary antibodies (Tables 16, 17).  
Table Gel Preparation 
 7% Run gel Stacking gel 
Distilled water 5.05 ml 2.95 ml 
1.5 M Tris- HCL pH 8.8 2.5 ml - 
0.5 M Tris- HCL pH 6.8 - 1.25 ml 
10% (w/v) SDS 0.1 ml 0.05 ml 
Acrylamide/ Bisacrylmide (30%/ 0.8% w/v);  Rotiphorese 30 2.6 ml 0.75 ml 
10% (w/v) Ammonium pre sulphate (APS) 0.05 ml 0.04 ml 
TEMED (Starter) 0.005 ml 0.01 ml 
Table 16: Reagents required for the preparation of SDS-PAGE. 
Separation of proteins by size was done in 7% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), by incubating the sample with loading buffer at 95oC for 5 min, 
centrifugation at 10,000 RPM for 10 sec, and running the processed samples on the gel at 100 volts 
for approximately an hour, or until the dye front ran close to the bottom of the gel.  
10X TBS buffer 
Tris base 200 mM 
NaCl 1.37M 
TBS-T washing buffer 
10× TBS buffer 100 ml/l 
Tween 20 1 ml/l 
10X Tris-Glycine Transfer Buffer 
Tris 10.25 M 
Glycine 1.92 M 
SDS (optional) 10.2% 
1X Transfer Buffer (1 Liter) 
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10 X transfer Buffer 100 ml 
Methanol 200 ml 
Distilled H2O 700 ml 
Blocking buffer 
Milk 5% 
10× TBS buffer 100 ml/l 
Tween 20 1 ml/l 
Stripping buffer 
-Mercaptoethanol 50 mM 
SDS 2% 
Tris HCl (pH 6.7) 62.5 mM 
Table 17: Buffers for Western blot analysis. 
3.9.6 Electrotransfer 
Proteins were transferred at 4°C onto a polyvinylidene fluoride membrane by electrotransfer for 
60 min at 400 milliamperes in a transfer tank containing transfer buffer (Table 17). 
3.9.7 Blocking and antibody incubation 
Detection of proteins of interest was performed using specific antibodies diluted in blocking buffer 
(Tables 17, 18). Blotted membranes were first placed on a horizontal shaker in blocking buffer for 
1 h at RT, followed by an overnight incubation at 4C with the primary antibodies against periostin 
(Table 18) and MMP13 (Table 18). After washing for three times in TBS-T washing buffer for 10 
min each to remove unbound antibodies, the membranes were incubated in the corresponding 
HRP-coupled secondary antibodies for 1 h at RT (Table 18). After another washing step, protein 
bands were detected using West Femto Chemiluminescence (SuperSignal™, Thermo Scientific™, 
Invitrogen) and visualized on a Bio-Rad Fluor-S MultiImager. Developed blots were semi-
quantitatively analyzed using the ImageJ 1.50e software (Wayne Rasband, National Institutes of 
Health, USA). 
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Table Antibody dilutions 
Antibody Source, Type Dilution 
Primary antibodies 
Periostin Rabbit, polyclonal 1: 500 
MMP13 Mouse, monoclonal 1: 500 
ß actin Mouse, monoclonal 1: 4000 
Secondary antibodies   
anti- Rabbit IgG-HRP Rabbit, polyclonal 1:1000 
anti- mouse IgG-HRP Mouse, monoclonal 1:1000 
 
Table 18: Primary and secondary antibodies and their dilutions for western blot analysis. 
3.9.8 Re-hybridization of membranes 
The membranes were re-probed to detect the control protein ß actin (Table 18). After removing 
the antibodies of the first immunoblotting in stripping buffer for 10 min at 60C and subsequent 
washing in TBS-T buffer (3 x; 10 min each), the membranes were blocked and probed with the 
primary and secondary antibodies for ß actin as described above (Table 18). 
3.10 Statistical analysis 
Data were expressed as medians ± 25th/75th and 5th/95th percentiles using box plots. Significance 
was tested using the non-parametric Kruskall-Wallis and Mann-Whitney U tests for the 2nd LB 
and the Wilcoxon test for the expression of silencing constructs (IBM SPSS Statistics 21 program; 
p ≤ 0.05). 
RESULTS 
38 
 
4 RESULTS 
4.1 Histological analysis of second look biopsies 
Second look biopsies (2nd LB) were obtained from patients with traumatic/degenerative cartilage 
defects who had undergone cartilage repair treatments such as ACT or MACT (n= 4; samples V9-
V12; Table 15). The patients displayed symptoms such as persistent joint swelling and/or pain, 
and the 2nd LB were taken during revision surgery. 
 
Sample 
No 
 
Gender 
(m/f) 
 
Age 
(years) 
 
Follow-
up 
(years) 
 
Pathology 
 
Type of  
therapy/ 
defect size 
(mm) 
 
Location/ 
ICRS grade 
 
Indication for 
2nd look biopsy 
 
Histology 
V9 f 38 
0.33 
(4 
months) 
Gonarthrosi
s/ 
reactive 
arthritis 
MACT 
(CaReS)/ 
3.5 x 2 cm 
(7 cm2) 
Medial 
femur 
condyle; 
left/ 
Grade IV 
Persistent 
crepitation; 
Recurrent 
swelling 
Connective 
tissue 
SO - 
V10 m 17 
2.8 
(2 years, 
10 
months) 
Osteochond
rosis 
dissecans 
ACT 
(Periostal 
flap)/ 
2 x 2 cm 
(4 cm2) 
Lateral 
femur 
condyle; 
left/ 
Grade IV 
Femoropatellar 
pain 
Degenerate
d cartilage 
SO + 
V11 f 47 
0.42 
(5 
months)  
Trauma/ 
gonarthrosi
s 
MACT 
(CaReS)/ 
5 cm2 
Retropatella
r; left/ 
Grade IV 
Persistent 
swelling and pain 
Connective 
tissue 
SO - 
V12 f 52 
8.0 
 
Chondropat
hy 
MACT/ 
1 - 4 cm2 
Medial 
femur 
condyle; 
right/ 
Grade IV 
Persistent 
swelling and pain 
Degenerate
d cartilage/ 
connective 
tissue 
SO (+) 
 
Table 19:  Characteristics of the patients with 2nd look biopsies. 
 
The 2nd LB were first histologically characterized using hematoxylin-eosin (HE) and Safranin 
O staining (SO).  
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HE staining of sample V9 showed characteristics of connective tissue rather than cartilage (Fig. 
5A), i.e., fibroblast morphology with a long, extended shape of nuclei and cytoplasm. The 20 X 
magnification showed regions with abundant EMC, partially organized in a concentric fashion 
(Fig. 5A). SO staining in the sample was completely negative (Fig. 5B). 
Figure 5: HE (A) and SO staining (B) of 2nd LB sample V9. 
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HE staining of sample V10 showed a high proportion of cartilage with marginal destruction and 
attached parts of connective tissue (Fig. 6A; overview and 4 X magnification). The 10 X and 20 
X magnifications displayed partially normal cartilage, but also regions of proliferating 
chondrocytes clusters as a sign of cartilage degeneration (or regeneration attempts) typical of 
progressive OA. There was a strong red staining with SO throughout most of the cartilage, 
indicating a mostly preserved, high content of charged molecules such as proteoglycans. 
Connective tissue regions were only counterstained in green (Fig. 6B).  
 
 
Figure 6: HE (A) and SO staining (B) of 2nd LB sample V10. 
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HE staining of sample V11 showed clear characteristics of pure connective tissue containing 
condensed, perivascular accumulations of mononuclear cells (Fig. 7A; in particular 10 X and 20 
X). Negative SO staining confirmed the connective tissue character (Fig. 7B). 
Figure 7: HE (A) and SO staining (B) of 2nd LB sample V11. 
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HE staining of sample V12 showed both cartilaginous regions and attached connective tissue 
regions (Fig. 8A). The connective tissue was partially surrounding and partially intruding the 
cartilage (Fig. 8A; in particular 4 X), similar to the cartilage destruction by the inflamed synovial 
membrane in OA and rheumatoid arthritis. The cartilage contained both seemingly normal 
regions and areas with proliferating chondrocyte clusters (Fig. 8A; in particular 20 X). Except for 
individual, positively stained chondrocyte nuclei, SO staining was negative (Fig. 8B). 
 
Figure 8: HE (A) and SO staining (B) of 2nd LB sample V12. 
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4.2 SOM expression portraits 
SOM expression portraits were generated using the complete set of Affymetrix expression data 
(Fig. 9).  D-cluster analysis of the SOM provided 7 clusters defining gene subsets containing 
between 183 and 740 genes. These sets were differentially expressed in 2nd LB, normal cartilage 
(tissue), OA cartilage (tissue), and 3D-cultured chondrocytes from normal cartilage (Fig. 9). 
Gene clusters S1 to S3 were similarly expressed in normal cartilage and 2nd LB. Set S1 
distinguished all cartilage tissue samples from 3D-cultured chondrocytes (up-regulation in 
cultured chondrocytes) and included cellular transporter genes (SLC7A11, SLC5A3). Set S2 
included genes down-regulated in 2nd LB (V9-V12) and normal cartilage (samples V13 to V16), 
e.g., transcription factors (e.g., RUNX1), genes influencing cartilage structural integrity (e.g., 
integrin-binding sialoprotein, carboanhydrase 2, microfibrillar associated protein 3), and 
inflammatory genes (e.g., CXCL14). Set S3 contained genes upregulated in 2nd LB and normal 
cartilage, which regulate chondrocyte development (e.g., insulin-like growth factor 1 receptor). 
Gene clusters S4 to S7 were differentially expressed in normal cartilage and 2nd LB, with an up-
regulation (S4, S5, S6) or down-regulation in 2nd LB (S7). Set S4 showed similarities of gene 
regulation in OA cartilage and 2nd LB, included several inflammatory genes (MHC-II molecules, 
macrophage markers, and chemokines such as CCL18, CXCL8), and showed large overlap with the 
GO gene set “inflammatory response” (not shown). Set S5 included genes interacting with the 
extracellular matrix (PALLD, MFAP5) and transcription factors (SOX18), and Set S6 contained 
interesting markers involved in matrix degradation (MMP7, MMP13, periostin), matrix 
regeneration (DPT, PENK) and mis-differentiation (collagens 1 and 10 alpha 1). This set showed 
considerable overlap with the GO gene set “extracellular matrix” (Fig. 10A, B). Expression of the 
genes in this GO gene set distinguished 2nd LB from normal cartilage (tissue) and chondrocytes 
cultured in monolayer for 0 days (Fig. 9, 10). Set S7 included genes regulating tissue architecture 
during wound healing (thrombomodulin, ICAM1, TNFRSF11B, EGR3, WIF1).  
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Thus, 2nd LB showed some similarities, but also considerable differences compared to normal 
cartilage and, also, shared some features with OA cartilage and 3D-cultured chondrocytes. 
Figure 9: SOM analysis of the Affymetrix chip data. A) SOM portraits of osteoarthritic cartilage 
(V4 to V8), normal cartilage (V1 to V3 and V13 to V16), 2nd LB following MACT (V9 to V12), and 
chondrocytes expanded in monolayer until the end of passage 0 (V26, V27), and then re-
differentiated in 3D culture in fibrinogen for 7 days (V17, 20, 23), 14 days (V18, 21, 24) or 21 days 
(V19, 22, 25; expression: red –green-blue codes for high-intermediate-low); B) D-clusters of the 
SOM defining gene sets S1-S7 with differential regulation among the samples; C) Expression score 
of the gene sets S1-S7 for all samples (expression: blue-brown codes for low-high; red frame 
indicating the samples further analyzed in Fig. 10). 
 
4.3 Validation of Affymetrix chip data by quantitative real-time PCR 
Comparative gene expression analysis by Affymetrix chips and RT-PCR confirmed the significant 
up-regulation of the degradation markers POSTN and MMP13 in 2nd LB (from S6; Fig. 10C, D). 
In contrast, the matrix regeneration markers DPT and PENK were only numerically upregulated 
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in 2nd LB according to the RT-PCR. However, there was a significant down-regulation of the 
wound healing marker ICAM 1 (from S7) in 2nd LB in the PCR results (Fig. 10C, D). The 
significantly increased expression of the connective tissue markers collagens 1, 3, and 5 alpha 1 
(2nd LB > normal cartilage by Affymetrix) was partially confirmed, and the lack of significant 
differences between 2nd LB and normal cartilage for the cartilage markers collagens 2 alpha 1 and 
9 alpha 2 was fully confirmed by RT-PCR. Also, the numerical increase of the cartilage marker 
ACAN in normal cartilage by Affymetrix was confirmed as a significant increase by RT-PCR (Fig. 
10C, D).  
Figure 10: Gene expression details (normal cartilage V13-16; 2nd LB V9-V12): A) The GO gene set 
‘extracellular matrix’ is closely related to subset S6, with 47/141 genes (33%) being part of S6 in 
the lower right metagene (20 x 20; compare with Fig. 9B); B) GSZ-score expression of the gene 
set ‘extracellular matrix’ for all samples (compare with Fig. 9C); C, D) Comparison of single gene 
expression based on Affymetrix chips (C) and RT-PCR (D); values are shown as medians ± 
25th/75th percentiles (boxes) and 5th/95th percentiles (whiskers); *P ≤ 0.05 versus normal 
cartilage; POSTN=periostin; MMP13=matrix metalloprotease 13; DPT=dermatopontin; PENK= 
proenkephalin; ICAM 1=intercellular adhesion molecule 1;COL1A1, COL2A1, COL3A1, COL5A1, 
and COL9A2=alpha 1 and 2 chains, respectively, of collagens 1, 2, 3, 5, and 9; ACAN=aggrecan. 
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4.4 Constitutive frequency of different periostin isoforms in OA chondrocytes 
All eight periostin isoforms were identified with different size PCR products in OA chondrocytes 
using primers widely spanning the periostin sequence (total periostin; E6 to E22; see Fig. 4 on 
page 17; Fig. 11A). Frequency analysis of each isoform by cloning resulted in high frequencies of 
approx. 30% for isoforms 3, 4, and 5, but lower frequencies for isoforms 1, 2, 6, 7, and 8 (≤ 3%; 
Fig. 11B). This was partially confirmed by isoform-specific RT-PCR (Fig. 4), resulting in 
frequencies  23% for isoforms 3, 4, 5, and 7, but ≤ 2% for isoforms 1, 2, 6, and 8 (Fig. 11C).   
   
4.5 Silencing of different periostin isoforms with the siRNA construct G05 
Qualitative analysis of the effects of periostin siRNA construct G05 (targeted to the isoforms 1, 2, 
3, 4, 5, 8; see Table 2 on page 17) on OA chondrocytes by gel electrophoresis showed a clear 
weakening of the gel bands for the isoforms 5/8 and 3/2, but a relative sparing of the bands for the 
isoforms 1, 4/6, and 7 on days 2 and 4 (Fig. 11D). This was largely confirmed by a numerical 
downregulation of the PCR signal for total periostin (1 outlier) and isoforms 2, 4, and 6, as well as 
a significant downregulation of isoforms 2, 5, and 8 on day 2 (Fig. 11F). On day 4, the isoform 
downregulation was still maintained, with significantly reduced signals for total periostin and 
isoforms 3 and 8, and numerically reduced levels for isoforms 2, 5, and, in part, 7 (Fig. 11 G).      
    
4.6 Silencing of the different periostin isoforms with the siRNA construct A02 
The periostin siRNA construct A02 (targeted to all eight isoforms; Table 2) led to a complete 
disappearance of all gel bands on day 2, but a gradual return of all bands on day 4 (Fig. 11E). This 
was confirmed by a significant or numerical downregulation of the PCR signals for total periostin 
and all isoforms on day 2 (P ≤ 0.05 for total periostin and isoforms 2, 3, 5, 6, 7, and 8; Fig. 11H) 
and on day 4 (P ≤ 0.05 for total periostin and isoforms 2, 3, 7, and 8; Fig. 11I).         
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Figure 11: Constitutive frequency of different periostin isoforms in OA chondrocytes, as assessed 
by SDS gels (A), cloning (B), and isoform-specific PCR (C). Effects of silencing with the siRNA 
constructs G05 and A02, as assessed by SDS gels (D, E), and isoform-specific PCR (F-I); *P ≤ 
0.05 versus silencing control. 
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4.7 Effects of periostin silencing on the expression of target genes of periostin 
Periostin silencing with the siRNA constructs G05 and A02 led to a transient, numerical or 
significant downregulation of the expression of the periostin target gene MMP13 on day 2 (to 80 
and 55%, respectively; P ≤ 0.05 versus silencing control for A02), with a subsequent return to 
baseline levels or above on day 4 (Fig. 12A, D). 
There were no significant effects of periostin silencing with either of the siRNA constructs on the 
expression of MMP3 on days 2 or 4 (Fig. 12B, E). 
In contrast to MMP13, interestingly, the target gene ICAM 1 was significantly upregulated by 
periostin silencing with both siRNA constructs on day 2 (2- and 5-fold, respectively) and in both 
cases remained numerically upregulated on day 4 (2- and 3-fold; respectively; Fig. 12C, F) 
Figure 12: Effects of periostin silencing with the siRNA constructs G05 and A02 on the expression 
of MMP13 (A, D), MMP3 (B, E), and ICAM 1 (C, F), as assessed by PCR; the dashed line 
indicates the expression level of the respective gene in the silencing control samples (100%); *P 
≤ 0.05 versus silencing control. 
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4.8 Effects of periostin silencing on the expression of marker genes 
Periostin silencing with the siRNA constructs G05 and A02 led to a numerical or significant 
upregulation of the expression of the cartilage-specific marker gene COL 2, but also the bone and 
wound healing marker COL 3 on day 2 (3-fold and 1.1-fold, respectively; P ≤ 0.05 versus silencing 
control for G05), which in both cases remained numerically upregulated on day 4 (3 fold and 5 -
fold, respectively; Fig. 13A to D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Effects of periostin silencing with the siRNA constructs G05 and A02 on the expression 
of COL 2 (A, C) and COL 3 (B, D; PCR); the dashed line indicates the expression level of the 
respective gene in the silencing control samples (100%); *P ≤ 0.05 versus silencing control. 
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4.9 Effects of periostin silencing on the protein expression of periostin and MMP13 
Periostin silencing with the siRNA constructs G05 and A02 led to a substantial, long-lasting, and 
significant suppression of the periostin protein levels in the supernatant of the silenced OA 
chondrocytes on days 2 and 4 (to 60 and 60 to 80%, respectively; P ≤ 0.05 versus silencing control 
for both siRNA constructs on days 2 and 4; Fig. 14A). 
Western blots confirmed a substantial reduction of the periostin protein levels in the cytoplasm of 
the silenced chondrocytes (shown for one representative patient; Fig. 14C). 
In addition, periostin silencing with the siRNA construct G05 led to a transient and significant 
suppression of the MMP13 protein levels in the supernatant of the silenced OA chondrocytes on 
day 2 (to 90%; P ≤ 0.05 versus silencing control; Fig. 14B), which was again largely confirmed in 
by Western blots in the cytoplasm of the silenced chondrocytes (Fig. 14C).   
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Figure 14: Effects of periostin silencing with the siRNA constructs G05 and A02 on the protein 
levels of periostin (A, C) and MMP13 (B, C) in the culture supernatant (A, B) and cytoplasm (C) of 
silenced OA chondrocytes (day 2), as assessed by ELISA (A, B) or Western blot (C); *P ≤ 0.05 versus 
silencing control. 
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5 DISCUSSION 
The aim of this project was to define biomarkers and functional pathways for the optimization of 
chondrogenic differentiation in stem cell-based MACT. This was pursued by comparing 2nd LB 
from patients with MACT/cartilage repair procedures to normal cartilage on one hand, and to bone 
marrow-derived, human MSC differentiating into chondrocytes on the other hand. The focus of 
our studies were potential deficits (e.g., de- or mis-differentiation) of successful and functional 
cartilage repair following MACT. As a first step, biomarkers and pathways of chondrogenic 
differentiation were defined in cartilage regenerates after MACT by generating an atlas of 
differential gene expression between 2nd LB and normal cartilage, OA cartilage, or 3D-cultured 
chondrocytes using Affymetrix microarrays and SOM. The molecules/pathways underlying 
impaired cartilage repair were then validated by PCR and gene ontology analysis. The functional 
importance of the periostin-Wnt-MMP13 pathway was assessed by silencing of periostin in OA 
chondrocytes and the analysis of target and phenotype genes at the RNA and protein level. This 
approach aimed at evaluating the potential value of this pathway for the improvement of cartilage 
repair procedures. 
The present study showed only limited similarity between 2nd LB and normal cartilage, and thus 
confirmed incomplete repair after cartilage replacement. On the other hand, similarities between 
2nd LB and OA cartilage regarding the expression of inflammatory response genes suggested a 
contribution of inflammatory processes to the incomplete defect healing. Furthermore, the 
overexpression of matrix degradation and mis-differentiation markers, including the periostin-
Wnt-MMP13 pathway, indicated molecular abnormalities accompanying insufficient cartilage 
repair. Indeed, successful counteraction (silencing) of periostin in OA chondrocytes led to transient 
downregulation of tissue-degrading MMP13 (mRNA and protein) and in upregulation of the 
cartilage marker collagen 2, pointing to a favorable effect of periostin silencing on the maintenance 
of the chondrogenic phenotype and the formation of mature cartilage. On the other hand, there was 
a transient upregulation of the wound healing markers ICAM 1 and collagen 3, raising the concern 
that downregulation of periostin may in parallel augment formation of wound healing and scar 
tissue.             
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5.1 Histological features of 2nd LB 
The histology of the individual 2nd LB showed mixed features of connective tissue and cartilage, 
confirming previous results on the histological, immunohistological, and electron microscopy 
analysis of 2nd LB and 3rd LB [56-58]. This tissue heterogeneity did influence the patterns of gene 
expression in the individual 2nd LB (data not shown), but did not prevent the identification of 
relevant molecules/pathways potentially involved in deficits of successful and functional cartilage 
repair. Since the histology of 2nd LB will always depend on the surgeon’s choice of tissue type and 
location, such heterogeneity is unavoidable and can only be balanced by including a higher number 
of samples [58]. However, the number of available 2nd LB is limited by the fact that second look 
re-arthroscopy following cartilage repair is only indicated upon complications such as persistent 
joint swelling and/or pain. 
5.2 Identification of differentially expressed biomarkers/pathways of cartilage regeneration 
Among other molecules/pathways, the periostin-Wnt-MMP13 pathway was identified by 
Affymetrix analyses and RT-PCR as one potentially relevant signaling pathways inhibiting the 
formation of fully mature regeneration cartilage. This is in agreement with previous publications 
on a potential role of periostin in matrix degradation and cartilage degeneration in OA [24, 59]. 
The Wnt pathway may also be also be targetable by non-toxic, small size chemical compounds 
such as CCT031374, which also inhibit the periostin induction of MMP13 expression [24], and 
may be usable instead of the complex, costly, and labor-intensive application of gene therapy 
approaches. Other differential clusters identified by Affymetrix arrays and SOM analysis included 
clusters containing markers of inflammation (S4), matrix interaction (S5), and the regulation of 
tissue architecture during wound healing (S7), providing the basis for future research concerning 
the promotion or suppression of cartilage regeneration. 
5.3 Constitutive frequency of different periostin isoforms in OA chondrocytes 
The present report for the first time showed a predominance of the isoforms 3, 4, 5, and 7 among 
the constitutively expressed periostin isoforms in OA chondrocytes. Some periostin isoforms 
appear to have specific functions during physiological or pathological tissue repair [26], cardiac 
remodeling [30], or lung embryogenesis [31], but there is currently no published information on 
the abundance or function of specific periostin isoforms in chondrocytes or cartilage. Future 
studies will have to compare the frequencies of periostin isoforms in normal and OA chondrocytes 
and possibly address specific isoform functions by directed silencing experiments. 
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5.4 Successful silencing of different periostin isoforms using different siRNA constructs 
In partial agreement with the presumed periostin isoform targets of the siRNA constructs G05 
(isoforms 1, 2, 3, 4, 5, 8) and A02 (all isoforms; see Fig 4), A02 led to a complete disappearance 
of all gel bands and a significant or numerical downregulation of the PCR signals for total periostin 
and all isoforms on day 2, whereas G05 showed a relative sparing of isoforms 6 and 7 on day 2 
(gel electrophoresis; PCR). This shows that the targeting of specific periostin isoforms is in 
principal possible, although due to possible interactions among the isoforms and the complex 
structure of exon-exon junctions in different periostin isoforms RNA silencing remains a complex 
molecular biological task (see Fig. 4). 
In the cases of both siRNA constructs, there was a gradual return of the periostin isoform 
expression to base line levels, in agreement with the limited half-life of the siRNA constructs. This 
also shows that the total dose and timing of applied siRNA have to be carefully titered to obtain 
reproducible results (data not shown; [60]). 
5.5 Effects of periostin silencing on the mRNA expression of periostin target genes 
The successful transient suppression of MMP13 expression by periostin silencing confirms 
published data [24], whereas the significant upregulation of ICAM 1 and cartilage-specific 
collagen 2 are reported for the first time in the present study. This supports the view that isolated 
silencing of periostin may have favorable effects on the chondrogenic phenotype and the formation 
of mature cartilage, but at the same time may augment the formation of scar tissue, as indicated by 
the upregulation of the wound healing markers ICAM 1 (4-6-fold) and collagen 3 (1.1-10-fold). 
This can be addressed by either inhibiting the periostin-Wnt-MMP13 pathway more thoroughly 
by a combination of different techniques or compounds [24], or else by inhibiting other target 
molecules in the identified relevant pathways, either alone or in combination with periostin.  
5.6 Effects of periostin silencing on the protein expression of periostin and MMP13 
Periostin silencing with both siRNA constructs resulted in a substantial, long-lasting, and 
significant suppression of the periostin protein levels in the cytoplasm and supernatant of the 
silenced OA chondrocytes, with a partially stronger effect of the siRNA A02 construct targeting 
all periostin isoforms. This shows that the present experimental design was well suitable to address 
the aims and questions of this study. 
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On the other hand, the suppression of the MMP13 protein production was transient (day 2) and 
only effective after silencing with the siRNA construct G05. This again emphasizes the importance 
of the exact experimental design and choice of target molecules for RNA silencing. 
 
6 CONCLUSIONS 
In the present study, biomarkers and pathways of impaired chondrogenic differentiation were 
defined in cartilage regenerates after MACT/cartilage repair procedures by comparative gene 
expression analysis in 2nd LB and normal cartilage using Affymetrix microarrays and 
bioinformatics. Relevant target molecules/pathways were then validated by PCR and gene 
ontology analysis. The functional importance of the identified periostin-Wnt-MMP13 pathway 
was demonstrated by downstream effects of periostin silencing in OA chondrocytes on the 
chondrogenic phenotype and the formation of mature cartilage, but also on the concurrent 
formation of wound healing and scar tissue. This shows that the aims of the study can be pursued 
by the current combination of translational and cell biology methods. However, further refinement 
of the therapeutic molecular targets is necessary to improve cartilage repair and develop novel 
treatments for articular cartilage defects. 
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